Deutsche Bank AG Acquires 669,614 Shares of Moderna, Inc. (NASDAQ:MRNA)

Deutsche Bank AG boosted its holdings in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 54.7% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 1,894,075 shares of the company's stock after acquiring an additional 669,614 shares during the period. Deutsche Bank AG owned 0.49% of Moderna worth $78,756,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in MRNA. Allworth Financial LP lifted its position in Moderna by 17.3% during the fourth quarter. Allworth Financial LP now owns 1,901 shares of the company's stock valued at $73,000 after buying an additional 281 shares during the period. Howard Capital Management Inc. increased its stake in shares of Moderna by 3.1% in the 4th quarter. Howard Capital Management Inc. now owns 9,994 shares of the company's stock worth $416,000 after acquiring an additional 297 shares in the last quarter. Itau Unibanco Holding S.A. lifted its position in Moderna by 51.2% during the 4th quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company's stock valued at $42,000 after acquiring an additional 343 shares during the period. Commonwealth Equity Services LLC grew its holdings in Moderna by 0.5% in the fourth quarter. Commonwealth Equity Services LLC now owns 74,520 shares of the company's stock worth $3,099,000 after purchasing an additional 345 shares during the period. Finally, Larson Financial Group LLC lifted its holdings in shares of Moderna by 39.1% during the fourth quarter. Larson Financial Group LLC now owns 1,266 shares of the company's stock valued at $53,000 after purchasing an additional 356 shares during the last quarter. Institutional investors own 75.33% of the company's stock.

Moderna Price Performance

MRNA stock opened at $24.25 on Monday. Moderna, Inc. has a 1 year low of $23.15 and a 1 year high of $170.47. The company has a market cap of $9.38 billion, a P/E ratio of -2.61 and a beta of 1.99. The stock's fifty day moving average price is $28.89 and its 200-day moving average price is $36.34.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share for the quarter, beating analysts' consensus estimates of ($2.92) by $0.40. The company had revenue of $108.00 million for the quarter, compared to the consensus estimate of $130.35 million. Moderna had a negative return on equity of 28.74% and a negative net margin of 110.04%. Moderna's revenue was down 35.3% on a year-over-year basis. During the same quarter in the prior year, the company earned ($3.07) earnings per share. As a group, analysts expect that Moderna, Inc. will post -9.61 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts recently weighed in on MRNA shares. Royal Bank of Canada reduced their price objective on Moderna from $32.00 to $28.00 and set a "sector perform" rating for the company in a research report on Friday, May 2nd. Citigroup initiated coverage on Moderna in a research note on Thursday, March 13th. They issued a "neutral" rating and a $40.00 target price on the stock. Leerink Partners lowered their price target on Moderna from $31.00 to $27.00 and set an "underweight" rating for the company in a research report on Thursday, January 16th. Bank of America cut their price objective on shares of Moderna from $41.00 to $34.00 and set an "underperform" rating on the stock in a research report on Tuesday, February 11th. Finally, Barclays reduced their price objective on shares of Moderna from $45.00 to $40.00 and set an "equal weight" rating for the company in a research note on Friday, May 2nd. Four research analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $53.95.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.